loading page

Possible Role of Advanced Glycation End Products (AGEs) In the Clinical Course of Prostate Neoplasies Among Patients with and without Type 2 Diabetes Mellitus
  • +6
  • Gamze Akkus,
  • Volkan Izol,
  • Fesih OK,
  • Mehtap Evran,
  • Merve Inceman,
  • Seyda Erdogan,
  • Halil Mahir Kaplan,
  • Murat Sert,
  • Tamer Tetiker
Gamze Akkus
Cukurova University
Author Profile
Volkan Izol
Cukurova University
Author Profile
Fesih OK
Cukurova University
Author Profile
Mehtap Evran
Cukurova University
Author Profile
Merve Inceman
Cukurova University
Author Profile
Seyda Erdogan
Cukurova University
Author Profile
Halil Mahir Kaplan
Cukurova University
Author Profile
Murat Sert
Cukurova University
Author Profile
Tamer Tetiker
Cukurova University
Author Profile

Abstract

Aim: The cognate receptor expression of AGE (RAGE; receptor for AGE) on malignant tissues in diabetic patients has been suggested as a co-factor in determining the clinical course and prognosis. We aimed to search this relationship between RAGE expression and clinicopathological features of prostate neoplasia. Methods: A total of 197 patients; 64 (diabetic n=24; non-diabetic n=40) with benign prostate hyperplasia, and 133 (diabetic n=71; non-diabetic n=62) with localized (LPCa)/metastatic prostate cancer (MetPCa) were included the study. The expression of RAGE was studied by immunohistochemically on prostate specimens. The RAGE score was assessed in the specimens according to the extent of immunoreactivity and staining intensity. Results: The RAGE scores of BPH patients (diabetic and non-diabetic) were found as negative. Patients with both LPCa and MetPCa showed significantly higher scores, respectively (LPCa and MetPCa vs. BPH; p<0.01). RAGE scores of diabetic patients with LPCa and MetPCa were found to be 4.71±3.14 and 4.97±3.69, respectively. RAGE scores of the non-diabetic patients who had LPCa and MetPCa were 1.52±1.87 and 1.69±1.58, respectively. When compared both groups with LPCa, RAGE scores of the diabetic patients were significantly higher than that of the non-diabetics (p=0.01). Similar results were revealed as for the patients with MetPCa (4.97±3.69 vs. 1.69±1.58 (diabetic vs. non-diabetic), respectively (p<0.01). Conclusion: We found a high rate of RAGE expression in malign prostate neoplasias to the BPH. Furthermore, as expected, higher scores were demonstrated in those with diabetes than non-diabetics. Disease progression and survival parameters were worse in the patients with high RAGE levels. RAGE may be useful in the diagnosis of prostate cancer and in determining its prognosis.

Peer review status:ACCEPTED

17 Aug 2020Submitted to International Journal of Clinical Practice
19 Aug 2020Submission Checks Completed
19 Aug 2020Assigned to Editor
20 Aug 2020Reviewer(s) Assigned
23 Aug 2020Review(s) Completed, Editorial Evaluation Pending
27 Aug 20201st Revision Received
29 Aug 2020Assigned to Editor
29 Aug 2020Submission Checks Completed
29 Aug 2020Reviewer(s) Assigned
31 Aug 2020Review(s) Completed, Editorial Evaluation Pending
02 Sep 20202nd Revision Received
03 Sep 2020Submission Checks Completed
03 Sep 2020Assigned to Editor
03 Sep 2020Reviewer(s) Assigned
03 Sep 2020Review(s) Completed, Editorial Evaluation Pending
11 Sep 2020Editorial Decision: Accept